Fujii Hideki, Kitada Takuya, Yamada Takao, Sakaguchi Hiroki, Seki Shuichi, Hino Masayuki
Third Department of Internal Medicine, Osaka City University Medical School, 1-4-3, Asahimachi, Abenoku, Osaka, 545-8585, Japan.
Hepatogastroenterology. 2003 May-Jun;50(51):841-2.
Although mild thrombocytopenia is a common adverse effect of interferon therapy, severe life-threatening thrombocytopenia is extremely rare. Here, we report a case of chronic hepatitis C patient that developed severe thrombocytopenia during alpha-interferon therapy, possibly due to an autoimmune mechanism. A 24-year-old female presented chronic hepatitis C in May, 1998. Based on the clinicopathological findings including a liver biopsy, administration of alpha-interferon was begun. In the fourth week of therapy, she experienced mild dyspnea and general fatigue. Complete blood count demonstrated thrombocytopenia (48,000/microL). Despite the immediate withdrawal of interferon, her platelet count further decreased to 1,100/microL. Bone marrow aspirate and elevated platelet-associated IgG antibodies were suggestive of immune thrombocytopenia. She was treated with intravenous and oral administration of steroids. Her platelet count returned to normal level 5 days later. Response to steroid treatment was consistent with the diagnosis of alpha-interferon-induced immune thrombocytopenia in this patient.
虽然轻度血小板减少是干扰素治疗常见的不良反应,但严重的、危及生命的血小板减少极为罕见。在此,我们报告一例慢性丙型肝炎患者,在α干扰素治疗期间出现严重血小板减少,可能是由于自身免疫机制所致。一名24岁女性于1998年5月被诊断为慢性丙型肝炎。根据包括肝活检在内的临床病理检查结果,开始给予α干扰素治疗。在治疗的第四周,她出现轻度呼吸困难和全身乏力。全血细胞计数显示血小板减少(48,000/微升)。尽管立即停用了干扰素,但其血小板计数进一步降至1,100/微升。骨髓穿刺和血小板相关IgG抗体升高提示免疫性血小板减少。她接受了静脉和口服类固醇治疗。5天后其血小板计数恢复至正常水平。对类固醇治疗的反应与该患者α干扰素诱导的免疫性血小板减少的诊断相符。